文献速递前列腺癌

他汀类药物与前列腺癌:炒作还是希望?流行病学视角

Statins and prostate cancer-hype or hope? The epidemiological perspective.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2022-06-22

多项注册研究和前瞻性队列研究发现,使用他汀类药物的男性晚期和致死性前列腺癌风险较低,已确诊前列腺癌者生存期更长。本文总结流行病学数据并讨论因果解释,综述脂质与非脂质介导机制,探讨可能获益的治疗场景和分子亚组。现有随机对照试验随访短、缺乏分子亚组,不足以为观察性结果提供额外支持。

要点

  • 前瞻性观察性研究一般报告他汀使用者致死性前列腺癌风险较低。
  • 有证据提示血清胆固醇降低是他汀与晚期和致死性前列腺癌关联的间接机制。
  • 少数随机对照试验随访短、缺乏分子亚组,不足以为观察性结果提供额外支持。

核心结论

  • 前瞻性和注册研究支持他汀使用者较非使用者晚期和致死性前列腺癌风险更低,前列腺癌患者结局更好。
  • 迄今少数随机对照试验随访短、缺乏已识别的分子亚组,未为观察性结果提供额外支持。
  • 需要额外证据确定哪些男性可能在前列腺癌特异性结局方面获益最大,以及他汀效应如何随分子肿瘤特征变化。

研究设计与样本

  • 本文为流行病学证据综述,总结他汀与前列腺癌的流行病学研究数据并讨论因果解释程度。
  • 综述脂质介导和非脂质介导的他汀潜在抗癌机制。
  • 探讨可能从前列汀使用中在前列腺癌特异性结局方面获益更多的治疗场景和分子亚组。

主要发现

  • 前瞻性观察性研究一般报告他汀使用者致死性前列腺癌风险较低。
  • 有证据支持血清胆固醇降低作为他汀与晚期和致死性前列腺癌关联的间接机制。
  • 机会窗口临床试验显示前列腺组织可测得他汀水平,提示直接效应可能。
  • 观察性数据提示他汀可能调节前列腺微环境炎症。
  • 注册研究新兴数据支持他汀在雄激素剥夺治疗和抗雄激素治疗背景下的潜在作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 迄今少数随机对照试验随访短。
  • 随机对照试验缺乏已识别的分子亚组。
  • 随机对照试验未为观察性结果提供额外支持。
  • 需要额外证据确定哪些男性获益最大及他汀效应如何随分子肿瘤特征变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Men using cholesterol-lowering statin medications have been found to have lower risks of both advanced and fatal prostate cancer in multiple registry-based studies and prospective cohort studies. Statin use has also been associated with longer survival among men already diagnosed with prostate cancer. Mechanisms responsible for purported anti-cancer effects of statins are not well understood but may offer insight into prostate cancer biology. METHODS: We summarise epidemiological data from studies of statins and prostate cancer and discuss to what extent these findings can be interpreted as causal. Additionally, lipid-mediated and non-lipid-mediated mechanisms that may contribute to potential anti-cancer effects of statins are reviewed. Finally, we consider treatment settings and molecular subgroups of men who might benefit more than others from statin use in terms of prostate cancer-specific outcomes. RESULTS: Data from prospective observational studies generally reported a lower risk of fatal prostate cancer among statin users. There is some evidence for serum cholesterol-lowering as an indirect mechanism linking statins with advanced and fatal prostate cancer. Window-of-opportunity clinical trials show measurable levels of statins in prostate tissue highlighting potential for direct effects, whilst observational data suggest possible statin-driven modulation of prostate microenvironment inflammation. Additionally, emerging data from registry studies support a potential role for statins within the context of androgen deprivation therapy and anti-androgen treatment. CONCLUSION: Prospective and registry-based studies support a lower risk of advanced and fatal prostate cancer in statin users relative to non-users, as well as better outcomes among prostate cancer patients. The few randomised-controlled trials conducted so far have short follow-up, lack identified molecular subgroups, and do not provide additional support for the observational results. Consequently, additional evidence is required to determine which men may experience greatest benefit in terms of prostate cancer-specific outcomes and how statin effects may vary according to molecular tumour characteristics.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Craig EL, Stopsack KH, Evergren E, et al. Statins and prostate cancer-hype or hope? The epidemiological perspective. Prostate Cancer Prostatic Dis. 2022. PMID: 35732821. doi:10.1038/s41391-022-00554-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。